BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

AGIO upcoming catalysts

Agios Pharmaceuticals, Inc.: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 2 FDA event(s). Subscribe to AGIO (.ics).

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-09-30PDUFA date (company-disclosed)date passedAGIOS PHARMACEUTICALS, INC. AGIOPDUFA September 30, 2026 - AGIOS PHARMACEUTICALS, INC.
2025-12-23FDA approvalapprovedAGIOS PHARMS INC AGIOAQVESME PYRUKYNDApproved 2025-12-23: AQVESME; PYRUKYND (NDA216196 SUPPL3)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-05-12P2Agios Pharmaceuticals, Inc. AGIONCT06924970 A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)Sickle Cell Diseaseactive not recruiting59
2026-03-17P2Agios Pharmaceuticals, Inc. AGIONCT05490446 A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)Myelodysplastic Syndromesactive not recruiting87

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.